FY2026 EPS Estimates for Axsome Therapeutics, Inc. Reduced by Leerink Partnrs (NASDAQ:AXSM)

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Investment analysts at Leerink Partnrs reduced their FY2026 earnings estimates for shares of Axsome Therapeutics in a note issued to investors on Monday, May 6th. Leerink Partnrs analyst M. Goodman now forecasts that the company will earn $1.60 per share for the year, down from their prior forecast of $1.85. The consensus estimate for Axsome Therapeutics' current full-year earnings is ($3.75) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics' FY2027 earnings at $7.95 EPS and FY2028 earnings at $11.40 EPS.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last issued its quarterly earnings results on Tuesday, February 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.21) by $0.48. Axsome Therapeutics had a negative net margin of 88.41% and a negative return on equity of 70.67%. The company had revenue of $71.53 million during the quarter, compared to analyst estimates of $70.38 million.

AXSM has been the subject of a number of other reports. Piper Sandler raised their price objective on shares of Axsome Therapeutics from $90.00 to $113.00 and gave the company an "overweight" rating in a research report on Tuesday, January 16th. HC Wainwright restated a "buy" rating and issued a $190.00 target price on shares of Axsome Therapeutics in a research note on Tuesday. Truist Financial reiterated a "buy" rating and set a $150.00 price target on shares of Axsome Therapeutics in a research report on Tuesday, March 26th. Robert W. Baird upped their price objective on shares of Axsome Therapeutics from $108.00 to $112.00 and gave the stock an "outperform" rating in a research report on Tuesday. Finally, UBS Group assumed coverage on shares of Axsome Therapeutics in a research note on Tuesday, February 6th. They issued a "buy" rating and a $111.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $121.92.

Axsome Therapeutics Stock Performance

Axsome Therapeutics stock traded down $1.26 during midday trading on Wednesday, reaching $75.68. The stock had a trading volume of 373,512 shares, compared to its average volume of 711,263. The firm has a market capitalization of $3.59 billion, a PE ratio of -14.55 and a beta of 1.13. Axsome Therapeutics has a 12 month low of $55.02 and a 12 month high of $98.40. The company has a quick ratio of 3.52, a current ratio of 3.63 and a debt-to-equity ratio of 0.93. The firm's 50-day moving average price is $73.99 and its 200 day moving average price is $75.73.

Insider Buying and Selling at Axsome Therapeutics

In related news, COO Mark L. Jacobson sold 24,662 shares of the company's stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $77.24, for a total value of $1,904,892.88. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, COO Mark L. Jacobson sold 24,662 shares of the company's stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $77.24, for a total value of $1,904,892.88. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Roger Jeffs sold 29,976 shares of the business's stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $69.70, for a total value of $2,089,327.20. Following the completion of the transaction, the director now owns 120,756 shares of the company's stock, valued at approximately $8,416,693.20. The disclosure for this sale can be found here. 24.50% of the stock is owned by company insiders.

Institutional Trading of Axsome Therapeutics

Several large investors have recently modified their holdings of AXSM. Principal Financial Group Inc. boosted its stake in shares of Axsome Therapeutics by 1.3% during the 4th quarter. Principal Financial Group Inc. now owns 9,497 shares of the company's stock worth $756,000 after acquiring an additional 120 shares during the last quarter. CIBC Private Wealth Group LLC lifted its position in Axsome Therapeutics by 0.8% during the fourth quarter. CIBC Private Wealth Group LLC now owns 17,999 shares of the company's stock valued at $1,433,000 after purchasing an additional 135 shares in the last quarter. Raymond James Financial Services Advisors Inc. grew its holdings in Axsome Therapeutics by 1.1% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 18,734 shares of the company's stock valued at $1,309,000 after purchasing an additional 197 shares during the period. Fifth Third Bancorp raised its stake in shares of Axsome Therapeutics by 100.0% in the third quarter. Fifth Third Bancorp now owns 400 shares of the company's stock worth $28,000 after buying an additional 200 shares during the period. Finally, Rafferty Asset Management LLC lifted its position in shares of Axsome Therapeutics by 4.7% during the 3rd quarter. Rafferty Asset Management LLC now owns 4,560 shares of the company's stock valued at $319,000 after buying an additional 205 shares in the last quarter. Institutional investors own 81.49% of the company's stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.